Park Medi World Q2 FY27 Revenue Up 25% to ₹511 Crore, PAT at ₹54.5 Crore
Park Medi World reported Q2 FY27 revenue of ₹511 crore, up 25% YoY, with PAT at ₹54.5 crore. H1 FY27 revenue grew 22% to ₹987 crore, PAT at ₹143 crore. The company added 680 beds and plans 750 more this year, expanding capacity by 40% in FY27. They anticipate negligible impact from cancer drug price capping.
The announcement details strong financial performance with substantial revenue and profit growth, coupled with aggressive capacity expansion plans. Positive outlook and strategic initiatives indicate a significant impact on the company's future prospects.
The company reported significant year-on-year growth in revenue and PAT, along with strategic capacity expansion plans. The management expressed confidence in future performance and negligible impact from regulatory changes.
Park Medi World Limited reported a robust performance for the quarter and half-year ended September 30, 2026. For the second quarter (Q2) of fiscal year 2027, revenue from operations grew by 25% year-on-year to ₹511 crore, with EBITDA at ₹102 crore (19.9% margin) and PAT at ₹54.5 crore (10.7% margin).
For the first half (H1) of FY27, revenue from operations reached ₹987 crore, a 22% increase year-on-year. EBITDA (excluding other income) stood at ₹228 crore (23.1% margin), and PAT was ₹143 crore (14.5% margin). The company served a record 5.39 lakh patients in H1 FY27.
Excluding the newly opened hospitals in Agra, Panchkula, and Rudrapur, the 14 established hospitals delivered a strong EBITDA margin of 26% and a PAT margin of 17% in H1 FY27. The company is on track to expand its bed capacity by 40% in FY27 over FY26, having added 680 beds so far and expecting to add another 750 beds by the end of the year.
Operational highlights for Q2 FY27 include a 31% year-on-year increase in IPD volume to 31,000 patients and a 29% rise in OPD to 259,000 patients. ARPOB increased by 13% to ₹30,646, and ALOS improved by 14% to 5.4 days. For H1 FY27, IPD and OPD volumes grew by 23% each. The company's case mix continues to shift towards high-end tertiary and quaternary care, contributing approximately 64% of revenue in Q2 FY27.
The company has invested ₹750 crore for adding 2,300 beds by December 2028, which will increase the total bed capacity to 6,590. The capex per bed is expected to remain within ₹30-35 lakh. The company anticipates negligible impact from cancer drug price capping and expects the CGHS rate hike to contribute approximately ₹58-60 crore in FY27.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.